title: Specificity of T cells invading the skin during acute graft-vs.-host disease after semiallogeneic bone marrow transplantation.
abstract: The mechanisms responsible for skin lesions during acute graft-vs.-host disease (aGVHD) after allogeneic bone marrow transplantation (BMT) are poorly understood. The exact role of various effector cell populations and "major" (particularly HLA-DP) or "minor" antigens as target molecules is not known. To investigate the nature of cells responsible for tissue injury, we cultured T cells from skin biopsy first with interleukin 2 (IL-2) alone and then in polyclonal activation conditions to avoid in vitro antigenic sensitization before specificity testing. We applied this method to two biopsies performed during aGVHD after semiallogeneic BMT and obtained cytotoxic T cells against four graft mismatches: CD8+ T cells against HLA-A2.2 and HLA-B27 and CD4+ T cells against HLA-DP101 and HLA-DP401. This demonstrates that T cells with documented specificity can be obtained from an aGVHD lesion without antigenic selection. Moreover, these data directly implicate DP as a potential target antigen for aGVHD.
authors.affiliation: Institut National de la Santé et de la Recherche Médicale Unité 211, CHR Nantes, France.
authors.forename: J
authors.initials: J
authors.lastname: Gaschet
authors.forename: B
authors.initials: B
authors.lastname: Mahé
authors.forename: N
authors.initials: N
authors.lastname: Milpied
authors.forename: M C
authors.initials: MC
authors.lastname: Devilder
authors.forename: B
authors.initials: B
authors.lastname: Dréno
authors.forename: J D
authors.initials: JD
authors.lastname: Bignon
authors.forename: F
authors.initials: F
authors.lastname: Davodeau
authors.forename: M M
authors.initials: MM
authors.lastname: Hallet
authors.forename: M
authors.initials: M
authors.lastname: Bonneville
authors.forename: H
authors.initials: H
authors.lastname: Vié
mesh_terms: D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D015139:Blotting, Southern; D016026:Bone Marrow Transplantation / Q000276:immunology*; D005260:Female; D015329:Gene Rearrangement, T-Lymphocyte; D006086:Graft vs Host Disease / Q000276:immunology*; D015234:HLA-A Antigens / Q000032:analysis; D015235:HLA-B Antigens / Q000032:analysis; D006682:HLA-DP Antigens / Q000032:analysis; D006683:HLA-DQ Antigens / Q000032:analysis; D006684:HLA-DR Antigens / Q000032:analysis; D006650:Histocompatibility Testing; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000601:surgery*; D015470:Leukemia, Myeloid, Acute / Q000276:immunology / Q000601:surgery*; D008213:Lymphocyte Activation; D008297:Male; D012867:Skin / Q000276:immunology* / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014184:Transplantation, Homologous
chemical_list: D015703:Antigens, CD; D015234:HLA-A Antigens; D015235:HLA-B Antigens; D006682:HLA-DP Antigens; D006683:HLA-DQ Antigens; D006684:HLA-DR Antigens